- Report
- July 2023
- 135 Pages
Global
From €5292EUR$6,000USD£4,649GBP
€6616EUR$7,500USD£5,812GBP
- Report
- July 2023
- 67 Pages
Global
From €2787EUR$3,160USD£2,449GBP
€3484EUR$3,950USD£3,061GBP
- Report
- February 2024
- 112 Pages
Global
From €4190EUR$4,750USD£3,681GBP
- Report
- November 2023
- 189 Pages
Global
From €3969EUR$4,500USD£3,487GBP
- Report
- May 2024
- 139 Pages
Global
From €4873EUR$5,524USD£4,281GBP
€5733EUR$6,499USD£5,036GBP
- Report
- June 2023
- 204 Pages
Global
From €3175EUR$3,600USD£2,790GBP
- Report
- June 2023
- 84 Pages
North America
From €1323EUR$1,500USD£1,162GBP
- Report
- June 2023
- 94 Pages
Africa, Middle East
From €1323EUR$1,500USD£1,162GBP
- Report
- June 2023
- 92 Pages
Asia Pacific
From €1323EUR$1,500USD£1,162GBP
- Report
- June 2023
- 92 Pages
Europe
From €1323EUR$1,500USD£1,162GBP
- Report
- December 2023
- 168 Pages
Global
From €4365EUR$4,949USD£3,835GBP
- Report
- November 2023
- 140 Pages
Global
From €3925EUR$4,450USD£3,448GBP
- Report
- February 2023
- 70 Pages
Global
From €3083EUR$3,495USD£2,708GBP

Opioid Use Disorder (OUD) is a type of addiction disorder that is characterized by the compulsive use of opioids, such as heroin, morphine, and prescription painkillers. OUD is a serious public health issue, with an estimated 2.1 million people in the United States suffering from the disorder. OUD is associated with a range of physical and psychological health problems, including an increased risk of overdose, infectious diseases, and mental health issues. Treatment for OUD typically involves a combination of medication-assisted treatment (MAT) and psychosocial interventions. MAT involves the use of medications, such as buprenorphine and methadone, to reduce cravings and withdrawal symptoms. Psychosocial interventions include cognitive-behavioral therapy, motivational interviewing, and 12-step programs.
Companies in the OUD market include Indivior, Alkermes, Orexo, and Braeburn Pharmaceuticals. Show Less Read more